Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 16Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Recurrence 13Multiple Myeloma 12Lymphoma, B-Cell 12Lymphoma, Non-Hodgkin 9Leukemia, Lymphocytic, Chronic, B-Cell 8Ovarian Neoplasms 7Lymphoma 7Burkitt Lymphoma 7Melanoma 5Lymphoma, Mantle-Cell 5Hematologic Neoplasms 5Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma, T-Cell 4Leukemia 3Graft vs Host Disease 3Uterine Cervical Neoplasms 2Sarcoma, Synovial 2Neuroblastoma 2Neoplasms, Plasma Cell 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lung Neoplasms 2Leukemia, T-Cell 2Hodgkin Disease 2Head and Neck Neoplasms 2Glioblastoma 2

Interventions

fludarabine 1Sensitivity and Specificity 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Prolymphocytic, T-Cell × fludarabine × Clear all
NCT04823091 2022-03-16

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Unknown
24 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡